References
- Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55: 61–6
- Ejlertsen B, Mouridsen HT, Jensen M-B, Andersen J, Jensen BB, Cold S, et al. Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. Eur J Cancer 2007; 43: 877–84
- Pavlakis N, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 1: CD003474; 2002.
- Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SR. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003; 30: 469
- Diel IJ, Solomayer E-F, Costa SD, Gollan C, Goerner R, Wallwiener D, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357–63
- Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-negative breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001; 19: 10–7
- Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002; 20: 3219–24
- Kokufu I, Kohno N, Takao M, Yamamoto M, Miyashita M, Kohno S, et al Adjuvant pamidronate therapy for the prevention of bone metastasis in breast cancer patients with four or more positive nodes. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004;22(14S):530.
- Jaschke A, Bastert G, Solomayer EF, Costa S, Schuetz F, Diel IJ. Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow: A longtime follow-up. Proc Am Soc Clin Oncol 2004; 23, abstract 529
- Colleoni M, O'Neill A, Goldhirsch A, Gelber RD, Bonetti M, Thürliman B, et al. Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol 2000; 18: 3925–35
- Fleich H. Bisphosphonates in bone disease. From the laboratory to the patient4th edn. Academic Press, San Diego 2000
- McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354: 821–31
- Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007; 25: 829–36
- Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Result from the Fracture Intervention Trial. JAMA 1998; 280: 2077–82
- Black DM, Delmas P, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809–22